"When we looked at the evolution of the buy side over the past five years, we saw that there was a gap in automation around collateral and how firms administer their OTC derivatives portfolios," explains Tim Lind, managing director of strategic planning at Omgeo.
According to Lind, it was preferable to make an acquisition rather than build collateral management functionality because of the speed at which the market is evolving.
Allustra was selected as it was "more suited to a buy-side impleme
Should regulators take a more active role when it comes to AI oversight, or leave it to the professionals? What will M&A look like in 2018?Subscribe to Weekly Wrap emails